Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) has received an average rating of “Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $13.17.
Several brokerages have weighed in on CLBT. Craig Hallum lifted their target price on Cellebrite DI from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, April 1st. William Blair upgraded Cellebrite DI from a “market perform” rating to an “outperform” rating in a research note on Wednesday, March 13th. JPMorgan Chase & Co. lifted their target price on Cellebrite DI from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Friday, May 24th. Lake Street Capital began coverage on Cellebrite DI in a report on Friday, April 19th. They issued a “buy” rating and a $13.00 price target for the company. Finally, Bank of America raised their price target on Cellebrite DI from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, April 1st.
Check Out Our Latest Research Report on Cellebrite DI
Hedge Funds Weigh In On Cellebrite DI
Cellebrite DI Stock Performance
NASDAQ:CLBT opened at $11.86 on Friday. The stock’s 50 day moving average price is $11.27 and its 200 day moving average price is $10.44. Cellebrite DI has a 52-week low of $6.36 and a 52-week high of $12.67.
Cellebrite DI (NASDAQ:CLBT – Get Free Report) last released its quarterly earnings results on Thursday, May 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. Cellebrite DI had a positive return on equity of 417.94% and a negative net margin of 32.57%. The firm had revenue of $89.60 million for the quarter, compared to the consensus estimate of $85.34 million. During the same quarter last year, the business posted $0.03 EPS. The firm’s quarterly revenue was up 25.8% compared to the same quarter last year. As a group, equities research analysts predict that Cellebrite DI will post 0.34 EPS for the current year.
Cellebrite DI Company Profile
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Further Reading
- Five stocks we like better than Cellebrite DI
- Why is the Ex-Dividend Date Significant to Investors?
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- Ride Out The Recession With These Dividend KingsĀ
- Progress Software Stock Back in the Green After Beating Forecasts
- Top Biotech Stocks: Exploring Innovation Opportunities
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.